Hypertension: Treatments, diabetes, and developing regions

The Lancet

Volumn 380, Issue 9841, 2012, Pages 539-541

  Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DEVELOPING COUNTRY; DIABETES MELLITUS; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALDOSTERONISM; LIFESTYLE; METABOLIC SYNDROME X; NOTE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SLEEP DISORDERED BREATHING; SPHYGMOMANOMETER; SYSTOLIC BLOOD PRESSURE;

EID: 84864863955     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61219-7     Document Type: Note

References (22)

1. Ezzati M, Lopez AD, Rodgers A, Hoorn SV, Murray CJL, for the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-60. (Pubitemid 35341298)
2. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23. (Pubitemid 40138015)
4. Tran CL, Ehrmann BJ, Messer KL, et al. Recent trends in healthcare utilization among children and adolescents with hypertension in the United States. Hypertension 2012; published online June 18. http://dx.doi.org/10.1161/ HYPERTENSIONAHA.111.188813.
5. Cloutier L, Schiffrin EL. Hypertension prevalence and control: impact of method of blood pressure measurement. Curr Cardiovasc Risk Rep 2012; 6: 267-73.
6. Leenen FH, Schiffrin EL. Control rates of hypertension in North America. Hypertension 2010; 56: 571-72.
7. Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012; 380: 591-600.
8. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet 2012; 380: 601-10.
9. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet 2012; 380: 611-19.
10. Chapman N, Dobson J, Wilson S, et al, for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-45. (Pubitemid 351664214)
11. Roush GC, Holford TR, Guddati AK. Meta-analysis of diuretic trials, chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110-17.
12. National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. NICE clinical guideline CG127-issued August, 2011. http://www.nice.org.uk/guidance/CG127 (accessed July 16, 2012).
13. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-17.
14. Tarnow L, Rosing P, Gall M-A, Nielsen FS, Parving H-H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-51. (Pubitemid 24324966)
15. Danaei G, Finucane MM, Lu Y, et al, for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
16. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-52. (Pubitemid 37553153)
17. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society Of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87. (Pubitemid 46924065)
18. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-85.
19. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-40. (Pubitemid 47362321)
20. Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk and therapy. Can J Cardiol 2012; 28: 270-87.
21. WHO. WHO Global Report. Preventing chronic disease: a vital investment. Geneva: World Health Organization, 2005.
22. Fagard RH, Grassi G, Hall J, et al. International Society of Hypertension Low and Middle Income Countries Committee: review of the goals of the committee and 5 years of ISH activities in low and middle income countries. J Hypertens 2010; 28: 635-36.